ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Assessment of multimodal CEST, perfusion and diffusion MRI for predicting clinical outcome of patients with diffuse glioma following surgery at baseline before radiotherapy.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the predictive value of different chemical exchange saturation transfer (CEST) contrasts, i.e. of the amide proton transfer (APT), relayed nuclear Overhauser effect (rNOE), and semi-solid magnetization transfer (ssMT), as well as of clinical routine perfusion- and diffusion-weighted MRI, in terms of treatment outcome in patients with glioma following surgery at baseline before radiotherapy at 3 T. MATERIALS AND
methodsFrom September 2018 to December 2022, 78 study participants (median age 62 years, 27/78 female) prospectively underwent CEST, diffusion, and perfusion imaging. CEST contrasts were reconstructed for the APT-weighted magnetization transfer ratio asymmetry (APTwasym), relaxation-compensated CEST metrics (MTRRexAPT, MTRRexNOE, MTRRexMT), and MTconst. Contrast-enhancing and whole tumor volumes were segmented on T2w-FLAIR and T1w images. Associations of mean contrast values with therapy response were tested using ROC analyses, while relationships with progression-free survival (PFS, median 6.04 months) and overall survival (OS, median 11.58 months), as well as added benefit compared to nCBV and ADC maps, were assessed using dichotomized Cox regression models.
resultsMTRRexAPT, MTRRexNOE, and MTRRexMT were associated with therapy response (AUC = 0.82, 0.81, 0.68; all p ≤ 0.03), PFS (HR = 2.92, 0.37, 3.40; all p ≤ 0.02), and OS (HR = 2.76, 0.63, 8.09; all p ≤ 0.05). MTconst was correlated with OS (HR = 5.52, p < 0.01), while APTwasym was linked to therapy response (AUC = 0.71, p = 0.02). MTRRexMT (χ² = 13.71, p < 0.01) and MTconst (χ² = 5.62, p = 0.018) provided each additional value to nCBV for OS prediction.
conclusionRelaxation-compensated CEST imaging of the APT, rNOE, and ssMT, as well as conventional APTwasym showed ability to predict treatment outcome, whilst ssMT-weighted imaging provided added benefit for OS prediction in patients with diffuse glioma following surgery at baseline before radiotherapy at 3 T.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.